Read by QxMD icon Read

ca prostata

shared collection
27 papers 0 to 25 followers avances
Matthias Eiber, Wolfgang P Fendler, Steven P Rowe, Jeremie Calais, Michael S Hofman, Tobias Maurer, Sarah M Schwarzenboeck, Clemens Kratowchil, Ken Herrmann, Frederik L Giesel
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-urea-based PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both 68 Ga- and 18 F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Boris Hadaschik, Martin Boegemann
No abstract text is available yet for this article.
May 18, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Anna Yordanova, Anja Becker, Elisabeth Eppard, Stefan Kürpig, Christian Fisang, Georg Feldmann, Markus Essler, Hojjat Ahmadzadehfar
BACKGROUND: [177 Lu]Lu-PSMA-617 is a well-tolerated therapy for the treatment of metastatic prostate cancer. However, because of the mainly renal excretion of the tracer, the kidneys are one of the most limiting organs. The purpose of this study was to examine the post-therapeutic changes in renal function over time and to identify risk factors for developing renal toxicity. We also tested the reliability of markers for renal function monitoring. METHODS: Fifty-five patients with castrate-resistant metastatic prostate cancer treated with at least three cycles of [177 Lu]Lu-PSMA-617 were investigated...
August 2017: European Journal of Nuclear Medicine and Molecular Imaging
Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Manal Sayeg, Yevgeniy Leshch, Hans-Juergen Wester, Richard P Baum
A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68 Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177 Lu-PSMA ligands. 68 Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Jan Herden, Isabell Heidegger, Pia Paffenholz, Daniel Porres
The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and biological aggressiveness of the disease...
2015: Oncology Research and Treatment
Richard P Baum, Harshad R Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Mueller, Ingo Klette, Hans-Jürgen Wester
UNLABELLED: The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) ((68)Ga-PSMA) PET/CT was used for patient selection and follow-up after PSMA RLT...
July 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Thubeena Manickavasagar, Clare Gilson, Simon Chowdhury, Roger Kirby
Metastatic prostate cancer is still commonly a lethal condition. The concept that 'men with prostate cancer die with rather than of their cancer' has been shown to be false. It is estimated that 10-20% of men in the UK present with locally advanced disease. Median overall survival remains only 3.5 years for men presenting with metastatic disease. The use of LHRH analogues to achieve medical castration has become the gold standard for both locally advanced prostate cancer, combined with radiotherapy, and metastatic disease...
April 2015: Practitioner
Francesco Ceci, Christian Uprimny, Bernhard Nilica, Llanos Geraldo, Dorota Kendler, Alexander Kroiss, Jasmin Bektic, Wolfgang Horninger, Peter Lukas, Clemens Decristoforo, Paolo Castellucci, Stefano Fanti, Irene J Virgolini
PURPOSE: To assess the association between PSA levels, PSA kinetics and other factors and a pathological (68)Ga-PSMA PET/CT scan in patients with recurrent prostate cancer (rPCa) with biochemical relapse (BR) after radical therapy. METHODS: Seventy consecutive rPCA patients referred for (68)Ga-PSMA PET/CT, matching all the following criteria, were retrospectively evaluated: (a) previous radical prostatectomy or primary radiotherapy with curative intent; (b) BR or persisting high PSA levels after primary treatment; and (c) complete clinical and imaging information...
July 2015: European Journal of Nuclear Medicine and Molecular Imaging
Florian Sterzing, Clemens Kratochwil, Hannah Fiedler, Sonja Katayama, Gregor Habl, Klaus Kopka, Ali Afshar-Oromieh, Jürgen Debus, Uwe Haberkorn, Frederik L Giesel
PURPOSE: Radiotherapy is the main therapeutic approach besides surgery of localized prostate cancer. It relies on risk stratification and exact staging. This report analyses the potential of [(68)Ga]Glu-urea-Lys(Ahx)-HBED-CC ((68)Ga-PSMA-11), a new positron emission tomography (PET) tracer targeting prostate-specific membrane antigen (PSMA) for prostate cancer staging and individualized radiotherapy planning. METHODS: A cohort of 57 patients with prostate cancer scanned with (68)Ga-PSMA-11 PET/CT for radiotherapy planning was retrospectively reviewed; 15 patients were at initial diagnosis and 42 patients at time of biochemical recurrence...
January 2016: European Journal of Nuclear Medicine and Molecular Imaging
Joyce M van Dodewaard-de Jong, Daniela E Oprea-Lager, Lotty Hooft, John M H de Klerk, Haiko J Bloemendal, Henk M W Verheul, Otto S Hoekstra, Alfons J M van den Eertwegh
CONTEXT: The majority of patients with castration-resistant prostate cancer develop bone metastatic disease. It is often challenging to optimally palliate malignant bone pain. In case of multifocal pain due to diffuse osteoblastic metastases, treatment with bone-seeking radiopharmaceuticals can be considered. OBJECTIVE: This systematic review evaluates the efficacy of different bone-seeking radiopharmaceuticals for palliation of malignant bone pain from prostate cancer...
September 2016: European Urology
Tilman Todenhöfer, Arnulf Stenzl, Lorenz C Hofbauer, Tilman D Rachner
Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown to improve bone mineral density (BMD) and to reduce the risk of fractures. For patients with bone metastases, both zoledronic acid and denosumab delay skeletal related events (SREs) in the castration resistant stage of disease...
2015: International Journal of Endocrinology
Enza Capasso, Silvia Durzu, Sara Piras, Shahin Zandieh, Peter Knoll, Alexander Haug, Marcus Hacker, Carlo Meleddu, Siroos Mirzaei
AIM: The presence of an elevated copper concentration in cancer cells may be potentially used to differentiate healthy from transformed cells. In this study, we aimed to look at the possible role of (64)CuCl2 PET/CT in staging of patients with prostate cancer (PC). METHODS: Seven patients affected by histologically confirmed PC have been prospectively enrolled. Three patients underwent adrenal deprivation therapy (ADT) at time of imaging. The remaining four patients had no ADT, surgery, or external beam radiation therapy (EBRT)...
July 2015: Annals of Nuclear Medicine
Joyce M van Dodewaard-de Jong, Henk M W Verheul, Haiko J Bloemendal, John M H de Klerk, Michael A Carducci, Alfons J M van den Eertwegh
Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223...
August 2015: Clinical Genitourinary Cancer
A S Merseburger, A Böker, M A Kuczyk, C-A von Klot
Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant disease. 5 years ago cytotoxic chemotherapy with docetaxel was the only life-prolonging treatment option in this situation. In the last 5 years, the results of randomised phase III studies have led to the approval of 5 new agents for the treatment of metastatic castration resistant prostate cancer (mCRPC)...
January 2015: Aktuelle Urologie
M Picchio, P Mapelli, V Panebianco, P Castellucci, E Incerti, A Briganti, G Gandaglia, M Kirienko, F Barchetti, C Nanni, F Montorsi, L Gianolli, S Fanti
Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after treatment, but it is not able to provide a clear distinction between locoregional and distant disease. Molecular and functional imaging, that are able to provide a detailed and comprehensive overview of PCa extension, are more reliable tools for primary tumour detection and disease extension assessment both in staging and restaging. In the present review we evaluate the role of PET/CT and MRI in the diagnosis, staging and restaging of PCa, and the use of these imaging modalities in prognosis, treatment planning and response assessment...
April 2015: European Journal of Nuclear Medicine and Molecular Imaging
J Cassinello, M A Climent, A González del Alba, B Mellado, J A Virizuela
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged: pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years...
December 2014: Clinical & Translational Oncology
Philip Geoffrey Turner, Joe O'Sullivan
INTRODUCTION: Bone metastases are a frequent complication of many malignancies and are particularly common in metastatic prostate cancer, where they are associated with a high degree of morbidity. Until recently, treatments relied on palliative bone targeting measures with no proven survival-prolonging action or on systemic agents with general anti-prostate cancer activity but significant toxicities. Radium-223 dichloride is a bone-seeking, α-emitting, radionuclide that has recently been licensed in the US and Europe for the treatment of men with castration-resistant prostate cancer, bone metastases and no known visceral metastases...
October 2014: Expert Opinion on Pharmacotherapy
Ethan Basch, D Andrew Loblaw, Thomas K Oliver, Michael Carducci, Ronald C Chen, James N Frame, Kristina Garrels, Sebastien Hotte, Michael W Kattan, Derek Raghavan, Fred Saad, Mary-Ellen Taplin, Cindy Walker-Dilks, James Williams, Eric Winquist, Charles L Bennett, Ted Wootton, R Bryan Rumble, Stacie B Dusetzina, Katherine S Virgo
PURPOSE: To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). METHODS: The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature. RESULTS: When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases)...
October 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
V Grünwald, M Rickmann
Recent years have seen dramatic changes in the biological understanding and treatment of solid tumors. Based on the tumor biology, targeting agents have been developed which directly affect the underlying genetic or immunological changes found in specific tumor entities. Significant increases in survival have delivered the functional proof of the concept of targeted and immunological tumor therapy. The management and adherence of the patient as well as optimized cooperation with clinicians are decisive for the results of therapy and disease control...
October 2014: Der Internist
2014-09-13 22:13:57
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"